Omeros (NASDAQ:OMER) Earns Hold Rating from Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Omeros (NASDAQ:OMER) in a report issued on Tuesday morning,Benzinga reports.

Other analysts have also issued research reports about the company. StockNews.com lowered Omeros from a “hold” rating to a “sell” rating in a report on Friday, March 21st. D. Boral Capital reissued a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research note on Tuesday. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Omeros currently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Price Performance

OMER opened at $7.36 on Tuesday. Omeros has a 1-year low of $2.97 and a 1-year high of $13.60. The stock has a market cap of $426.51 million, a P/E ratio of -3.19 and a beta of 2.03. The stock’s 50 day simple moving average is $8.58 and its 200 day simple moving average is $7.61.

Institutional Trading of Omeros

Several large investors have recently bought and sold shares of the company. Truvestments Capital LLC lifted its position in shares of Omeros by 116.5% during the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 1,972 shares during the period. Quantbot Technologies LP bought a new position in shares of Omeros in the 4th quarter worth about $46,000. Picton Mahoney Asset Management boosted its holdings in shares of Omeros by 692.5% in the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 4,404 shares during the period. Finally, US Bancorp DE bought a new stake in shares of Omeros during the 4th quarter valued at about $81,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.